Empowering staff at the point of care: Improving safety, and fighting COVID
Post-money valuation ⓘ
$9.5M
As of Apr 2025 · from Reg CF Offering (2024) · pre-money + amount raised, not a traded price
Total raised
$36,722,579
Crowd $5.8M · Private $30.9M · 18 rounds since 2016
Latest share price
$0.0569
Reg CF · Preferred Stock · Aug 2024 offering price · down round
Financials
FY2018–FY2025 · from SEC filings · hover any figure for its source
$231K
−$1.3M
2018
$604K
−$1.1M
2019
$1.0M
−$1.3M
2020
$1.2M
−$3.0M
2021
$1.5M
−$4.0M
2022
$1.7M
−$5.0M
2023
$2.4M
−$2.5M
2024
$2.6M
−$1.4M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018 reviewed
FY2019 reviewed
FY2020
FY2021
FY2022 audited
FY2023 audited
FY2024 unaudited
FY2025 unaudited
Income statement
Revenue
$231,233
$603,763
$1,047,195
$1,163,372
$1,515,596
$1,718,775
$2,420,278
$2,623,648
Cost of goods sold
$11,828
$152,673
$334,204
$598,935
$839,123
$1,347,484
$895,621
$658,471
Gross margin
95%
75%
68%
49%
45%
22%
63%
75%
Net income
-$1,308,443
-$1,116,953
-$1,349,246
-$3,022,531
-$4,006,183
-$5,038,549
-$2,537,697
-$1,445,890
Taxes paid
$800
$800
$800
$10,322
$3,363
$4,696
$12,117
$3,206
Balance sheet
Cash
$326,524
$251,677
$1,905,551
$588,759
$3,627,979
$2,900,788
$864,994
$333,284
Accounts receivable
$12,500
$214,142
$156,000
$410,275
$244,140
$226,850
$724,310
$222,322
Total assets
$395,040
$542,441
$2,260,504
$1,067,977
$4,075,376
$3,306,630
$1,781,406
$715,215
Short-term debt
$0
$25,620
$38,743
$33,459
$761,498
$1,716,673
$2,037,778
$1,732,939
Long-term debt
$702,726
$1,509,807
$1,705,225
$35,000
$0
$0
$5,000
$2,500
Total liabilities
$702,726
$1,535,427
$1,743,968
$68,459
$761,498
$1,716,673
$2,042,778
$1,735,439
Other
Headcount
—
12
23
26
—
20
—
18
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came in
$12.0M
Valuation cap
$20.0M
pre-money
$6.0M
pre-money
Reg CF · SAFE · Apr 2020
Reg CF · Common · Jul 2021
Reg CF · Preferred · Aug 2024
Blue bars are the pre-money valuation the company stated for a priced round. Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth, so don't compare them with the other bars.
Share price over rounds
log scale
$0.86$0.2212$0.0569
Jun 2021Aug 2024
Round offering price or verified disclosed saleDisclosed sale, unverified or year-onlyDown round · Aug 2024 (-93.4%)
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2023
These classes don't convert into each other and last sold at very different prices, so their share counts can't be added up into ownership percentages. Compare them by price instead.
Class
Outstanding
Votes / share
Liquidation
Last price
Series Seed Preferred Stockpreferred
52,359,098
—
—
$0.86Jul 2021
Series A-1 Preferred Stockpreferred(as of Dec 31, 2022)
44,167,464
—
—
—
Preferred stockpreferred
1,903,630
—
1× non-participating
—
Series A-2 Preferred Stockpreferred(as of Dec 31, 2022)
1,707,235
—
—
—
Common Stock
2,214,708
—
—
$0.0569Aug 2024
Principal holders% as the filing states it, Apr 6, 2026
SJF Ventures V, L.P.74,156,549 Series Seed AA-1 Preferred; Series Seed Preferred58.3%of votes
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Dr. Roy-Burman has spent 20 years in ICU leadership at the nation’s top medical centers.
Scott M. Cohen, MHAFounder
Chief Operating Officer
Cohen spent 13 years as VP Client Development at athenahealth, from early stage to over $1 Billion in revenue.
LH
Linda T Hand
Chief Executive Officer
Carole A. Klove, RN, JD
Chief Nursing Officer
Former Chief Compliance & Privacy Officer at Stanford and UCLA. Alumni Board of Directors, Duke School of Nursing.
ML
Madison Lyford
CFO
Elliott Nguyen
Head of People and Process
Elemeno’s first Client Success Manager set a high bar and now leads recruitment for our expanding team.
Lisa Crounse
VP, Product
Former Head of Product at Modsy. Former Sr. Product Line Manager at Autodesk, overseeing platform portfolio roadmap supporting 12 million annual installs.
Sandra Frykman, RN
Regional VP, Sales
Former Head of Sales at Incredible Health. Distinguished career in health tech sales, driving growth at McKesson, Allscripts, Vivian Health, and more.
Steve Mundro
VP, Engineering
Developed social games serving millions of users at Game Show Network, and internal and customer tools managing millions of dollars at Alphaflow.
Show 28 more peopleShow fewer
Victoria G. Watts
VP, Client
Former VP of Customer Success & Sales Operations at McKesson. Former VP of Customer Success at Incredible Health.
Alice Muwonge
Client Success Manager
Andrey Shrayev
Lead Portal Engineer
Andy Fitzgerald
Information Architecture & Strategy
Ann Scott Blouin, RN, PhD, FACHE
Advisory Board
Former EVP of Customer Relations and Accreditation at The Joint Commission
Bruce Auerbach, MD
Advisory Board
Past CEO and former VP & Chief of Emergency Medicine, Sturdy Memorial Hospital
Christian Kim
Content Production Associate
Christopher Olivia, MD, MBA
Advisory Board
CEO at Rothman Institute. Past President at Visiting Nurse Service of New York.
Crista Bailey
Board Director
Success from early stage CitySearch to startup CEO at Texture Media and turnaround CEO at Hideaway Report.
Cynthia Nunamaker, MHI, BSN, RN, CRN, EBP-C
Sr. Clinical Lead, Client Experience & Innovation
Long-time cardiac nurse turned nurse innovator at Ohio State Wexner Medical Center. Sought out Elemeno Health: “This is my dream job!”
Ed Nanale
Advisory Board
Technical Co-Founder, Elemeno Health. Engineering lead at Google and Electronic Arts.
Eirish Sison
Product Manager
Eric Uhrhane
Principal Software Engineer
Caltech engineer with distinguished career at early-stage Google and Google X.
Gordon Tang, MD
Advisory Board
Chair of Surgery, Sutter Alta Bates Medical Center
Jasmine Galeana
Client Success Manager
Jess Gorsuch
Content Production Associate
Jessica Sandow
Human Resources
Kate Walling
Marketing Project Manager
Founder & CEO, Traction Hero. Kate is leading build of our marketing team.
Kelley Spurr, MS, RN
Clinical Content Lead
Experienced nurse and manager at Penn and UCSF. Focus on technology solutions to support frontline staff, reduce variability, and improve outcomes.
Mary Beth Navarra-Sirio, RN, MBA
Advisory Board
Board of Directors, Institute for Healthcare Improvement. Past-Chair National Patient Safety Foundation.
Natalie Reed
Client Success Manager
Rachel Fish
Board Director
Chief People Officer and Former Chief of Staff, Clover Health
Rick Cochran
Sales Operations
Sales Operations leader in multiple industries, including tech, healthcare, and education. Startup founder and UT Austin deep tech incubator mentor.
Roxana Dhada
Lead Content Production Associate
Ted Ridgway
Board Observer
Co-Founder of Launchpad Digital Health and Former COO & CFO of KitCheck
Trevor Carpenter
Content Production Associate
AK
Arrun Kapoor
Board Director
AK
Alan Kelley
Board Member
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 3 of 6 annual reports (FY2020–FY2025)
4,072 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.
